Serum osteocalcin levels at four months of age were associated with neurodevelopment at four years of age in term‐born children

Abstract Objectives Boys with Duchenne Muscular Dystrophy (DMD) are at increased risk for compromised bone health, manifesting as low-impact trauma long bone fractures and vertebral compression fractures. Methods In a prospective observational study, we studied bone health parameters in North Indian boys with DMD. We consecutively enrolled ambulatory boys with DMD on glucocorticoid therapy. Bone health was evaluated with X-ray spine, Dual-energy X-ray absorptiometry (DXA), serum calcium, vitamin D3 (25[OH]D), 1,25-dihyroxyvitamin D3 (1,25[OH]2D3), serum osteocalcin, osteopontin, and N terminal telopeptide of type 1 collagen (Ntx) levels. Results A total of 76 boys with DMD were enrolled. The median age was 8.5 (interquartile range [IQR] 7.04–10.77) years. Among these, seven (9.2%) boys had long bone fractures, and four (5.3%) had vertebral compression fractures. Fifty-four (71%) boys underwent DXA scan, and among these 31 (57%) had low bone mineral density (BMD, ≤−2 z-score) at the lumbar spine. The mean BMD z-score at the lumbar spine was −2.3 (95% confidence interval [CI] = −1.8, −2.8), and at the femoral neck was −2.5 (95% CI = −2, −2.9). 25(OH)D levels were deficient in 68 (89.5%, n=76) boys, and 1,25(OH)2D3 levels were deficient in all. Mean serum osteocalcin levels were 0.68 ± 0.38 ng/mL (n=54), serum osteopontin levels were 8.6 ± 4.6 pg/mL (n=54) and serum Ntx levels were 891 ± 476 nmol/L (n=54). Boys with low BMD received glucocorticoids for longer duration, in comparison to those with normal BMD (median, IQR [16.9 (6–34) months vs. 7.8 (4.8–13.4) months]; p=0.04). Conclusions Bone health is compromised in North Indian boys with DMD. BMD at the lumbar spine is reduced in more than half of boys with DMD and nearly all had vitamin D deficiency on regular vitamin D supplements. Longer duration of glucocorticoid therapy is a risk factor for low BMD in our cohort.

Download Full-text

Serum Osteocalcin Concentrations in Paget's Disease of Bone

Archives of Internal Medicine ◽

10.1001/archinte.1986.00360140074010 ◽

1986 ◽

Vol 146 (2) ◽

pp. 268 ◽

Cited By ~ 24

Author(s):

Margaret R. Wilkinson

Keyword(s):

Paget’S Disease ◽

Paget's Disease ◽

Paget’S Disease Of Bone ◽

Serum Osteocalcin ◽

Paget's Disease Of Bone

Download Full-text

Follicle stimulating hormone and estradiol alter immune response in osteoarthritic mice in an opposite manner

International Journal of Immunopathology and Pharmacology ◽

10.1177/20587384211016198 ◽

2021 ◽

Vol 35 ◽

pp. 205873842110161

Author(s):

Lyudmila Belenska-Todorova ◽

Ralitsa Zhivkova ◽

Maya Markova ◽

Nina Ivanovska

Keyword(s):

Follicle Stimulating Hormone ◽

Endocrine System ◽

Synovial Cell ◽

Nuclear Factor Κb ◽

Cartilage Degradation ◽

Osteoclast Formation ◽

Blue Staining ◽

Serum Osteocalcin ◽

Tnf Α ◽

Stimulating Hormone

Although a number of studies have shown that the occurrence and progression of osteoarthritis (OA) is related to endocrine system dysfunction, there is limited evidence about what roles sex hormones play. The aim of the present study was to examine the capacity of 17β-estradiol (ED) and follicle stimulating hormone (FSH) to alter the differentiation of bone marrow (BM) cells in arthritic mice. The experiments were conducted in collagenase-induced osteoarthritis in mice. Cartilage degradation was observed by safranin and toluidine blue staining. Flow cytometry was used to define different BM and synovial cell populations. The influence of FSH and ED on osteoclastogenesis was studied in BM cultures and on the osteoblastogenesis in primary calvarial cultures. The levels of IL-8, TNF-α, FSH, and osteocalcin were estimated by ELISA. FSH increased cartilage degradation and serum osteocalcin levels, while ED abolished it and lowered serum osteocalcin. FSH elevated the percentage of monocytoid CD14+/RANK+ and B cell CD19+/RANK+ cells in contrast to ED which inhibited the accumulation of these osteogenic populations. Also, ED changed the percentage of CD105+/F4/80+ and CD11c+ cells in the synovium. FSH augmented and ED suppressed macrophage colony-stimulating factor (M-CSF) + receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast (OC) formation, and this correlated with a respective increase and decrease of IL-8 secretion. FSH did not influence osteoblast (OB) formation while ED enhanced this process in association with changes of TNF-α, IL-8, and osteocalcin production. ED reduced osteoclast generation in bone. The key outcome of the current study is that both hormones influenced BM cell differentiation, with FSH favoring osteoclast formation and ED favoring osteoblast accumulation.

Download Full-text

The effect of levothyroxine in comparison with placebo on serum osteocalcin levels in patients with subclinical hypothyroidism

Current Drug Safety ◽

10.2174/1574886316666210525102230 ◽

2021 ◽

Vol 16 ◽

Author(s):

Reihaneh Rezaee ◽

Masoud Mohebbi ◽

Mozhgan Afkhamizadeh ◽

Mohammad Ali Yaghoubi ◽

Mona Najaf Najafi ◽

...

Keyword(s):

Thyroid Hormones ◽

Subclinical Hypothyroidism ◽

Intervention Group ◽

Serum Levels ◽

Overt Hypothyroidism ◽

Serum Osteocalcin ◽

Significant Difference ◽

Before And After ◽

Metabolic Conditions ◽

And Control

Background and Objective: Subclinical hypothyroidism can potentially develop to overt hypothyroidism. Thyroid hormones have substantial roles in metabolism and glucose homeostasis and thus are closely related to determinant factors of metabolic syndromes, such as obesity and insulin resistance. Osteocalcin is considered a predictor of metabolic conditions in thyroid diseases. This study aimed to investigate the effect of levothyroxine vs. placebo on serum osteocalcin levels in patients with subclinical hypothyroidism. Methods: This randomized clinical trial was performed on 30 patients with subclinical hypothyroidism who were referred to the endocrine clinics of Ghaem and Imam Reza hospitals in Mashhad, Iran. After giving informed consent, patients were randomly divided into intervention (50 µg/day levothyroxine for 2 months) and control (placebo) groups. Serum levels of osteocalcin, thyroid hormones, lipid profile, insulin, and fasting glucose, as well as other clinical and anthropometric data, were measured at baseline and at the end of the study. SPSS was used to analyze the data and P<0.05 was considered significant. Results: Mean age in the intervention and control groups was 35.07 ± 9.94 and 31.30 ± 4.30, respectively (P=0.20). There was no significant difference between osteocalcin levels before and after the intervention in either of the groups (P=0.54). TSH level was significantly decreased in the levothyroxine group after the intervention (P<0.01). T4 level was significantly increased in the intervention group (P=0.02). Conclusion: Levothyroxine had no significant effect on increasing the levels of serum osteocalcin in patients with subclinical hypothyroidism. We have registered the trial in the Iranian registry of clinical trials (IRCT) with the registration code IRCT20171129037677N1.

Download Full-text

Abstract P111: Sleep duration is associated with serum osteocalcin level in an elderly Korean population: the Korean Urban and Rural Elderly (KURE) study

Circulation ◽

10.1161/circ.129.suppl_1.p111 ◽

2014 ◽

Vol 129 (suppl_1) ◽

Author(s):

Ju-Mi Lee ◽

Hansol Choi ◽

Kyung Min Kim ◽

YooSik Youm ◽

Yumie Rhee ◽

...

Keyword(s):

Bone Formation ◽

Sleep Duration ◽

Linear Regression Analysis ◽

Korean Population ◽

Health Examination ◽

Central Research ◽

Serum Osteocalcin ◽

Cross Sectional ◽

Osteocalcin Level ◽

Serum Osteocalcin Level

Importance: Association between sleep duration and health related outcome studies have been published consistently. However there have been few studies of the association between sleep duration and bone formation in elderly. Objective: The aim of this study is to examine association between sleep duration and serum osteocalcin level in an elderly Korean population. Design: Cross sectional analysis using baseline cohort data. Setting: Community based setting Participants: Among the total of 927 participants, we excluded 1 participant because of the absence on sleep duration answer. A final total of 926 participants (624 women and 302 men aged 64-87 years) who completed baseline health examination in 2012 were enrolled in this study. Measurement: Sleep duration was measured by interviewer-assisted questionnaire. Participants answered their regular time of going to bed, time of opening eyes in the morning, and time of regular nap using open questions during the passing year. Serum osteocalcin level, a known biomarker of osteogenesis, was measured by electrochemiluminescence immunoassay method in the central research laboratory. The association between sleep duration (minutes/day) and serum osteoclacin level (ng/ml) was assessed by multiple linear regression analysis. Results: In the total population, sleep duration had significant association with serum osteocalcin level (ß=-0.008, p=0.013). One hour increase in sleep duration was associated with 0.48 ng/ml increase in serum osteocalcin level. This association remained after controlling for age, sex, body mass index, cigarette smoking, alcohol drinking, physical activity, and serum 25(OH) vitamin D (ß=0.012, p<0.001). This association was consistent before and after adjusting confounders in women (ß=-0.010, p=0.019, ß=-0.011, p=0.009, respectively) and men (ß=-0.013, p=0.012, ß=-0.013, p=0.011, respectively). Conclusions: Our findings suggest that longer sleep duration is associated with higher bone formation process in an elderly of Korean.

Download Full-text

Clinical Evaluation of Bone Turnover by Serum Osteocalcin Measurements in a Hospital Setting*

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jcem-59-2-228 ◽

1984 ◽

Vol 59 (2) ◽

pp. 228-230 ◽

Cited By ~ 119

Author(s):

DAVID M. SLOVIK ◽

CAREN M. GUNDBERG ◽

ROBERT M. NEER ◽

JANE B. LIAN

Keyword(s):

Bone Turnover ◽

Clinical Evaluation ◽

Hospital Setting ◽

Serum Osteocalcin

Download Full-text

Comment on 'Association between serum osteocalcin and body mass index: a systematic review and meta-analysis.'

Endocrine ◽

10.1007/s12020-017-1456-5 ◽

2017 ◽

Vol 58 (3) ◽

pp. 595-596 ◽

Cited By ~ 1

Author(s):

Xiaoying Liu ◽

Kaye E. Brock ◽

Tara C. Brennan-Speranza

Keyword(s):

Systematic Review ◽

Body Mass Index ◽

Body Mass ◽

Meta Analysis ◽

Serum Osteocalcin

Download Full-text

Responses of Markers of Bone and Collagen Turnover to Exercise, Growth Hormone (GH) Administration, and GH Withdrawal in Trained Adult Males1

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jcem.85.1.6262 ◽

2000 ◽

Vol 85 (1) ◽

pp. 124-133 ◽

Cited By ~ 3

Author(s):

Jennifer D. Wallace ◽

Ross C. Cuneo ◽

Per Arne Lundberg ◽

Thord Rosén ◽

Jens Otto Lunde Jørgensen ◽

...

Keyword(s):

Acute Exercise ◽

Type I Collagen ◽

Controlled Study ◽

Bone Resorption Marker ◽

Type I ◽

Serum Osteocalcin ◽

Collagen Turnover ◽

Gh Treatment ◽

Type I Procollagen ◽

Procollagen Iii

To examine the interactions between acute exercise and GH on markers of bone and collagen turnover and to assess the potential for detecting GH abuse in athletes using these markers, we studied 17 aerobically trained males (age, 26.9 ± 1.5 yr). Sequential studies of exercise, GH administration, and GH withdrawal were undertaken. A randomized, controlled study of rest vs. exercise showed that exercise did not change serum osteocalcin; other markers of formation increased transiently (each P < 0.001): bone-specific alkaline phosphatase (+16.1%), carboxyterminal propeptide of type I procollagen (+14.1%), and procollagen III N-terminal extension peptide (+5.0%). The carboxyterminal cross-linked telopeptide of type I collagen, a bone resorption marker, increased 9.7% (P = 0.018) in response to exercise. A randomized, double blind, placebo-controlled, parallel study of recombinant human GH treatment (0.15 IU/kg·day) for 1 week increased serum osteocalcin (net increase preexercise, +10.0%; P = 0.017), carboxyterminal propeptide of type I procollagen (+17.6%; P = 0.002), procollagen III N-terminal extension peptide (+48.4%; P = 0.001), and carboxyterminal cross-linked telopeptide of type I collagen (53.3%; P = 0.009). Disappearance half-times after cessation of recombinant human GH for pre- and postexercise markers ranged from 248–770 h. We conclude 1) endurance exercise transiently activates bone and collagen turnover; 2) brief GH administration results in similar but quantitatively greater augmentation; and 3) these data will assist in designing a GH detection strategy.

Download Full-text